This month several ProQRians will attend the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022 to highlight our Axiomer® RNA-editing platform technology.
… focuses on developing potential medicines using our Axiomer RNA editing platform technology. Strategic … drive the advancement of an early-stage technology, like Axiomer, closer to the clinic. Today we are delighted to … announced in September 2021 , applied ProQR’s proprietary Axiomer® RNA editing platform to target disorders of the …
… immense, says Bart Klein, who was at the forefront of the Axiomer® technology development. ProQR’s Sr. Vice President Innovation makes his point about the promise of Axiomer® technology: “This opens up a whole new way of …
ProQR will focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple therapeutic areas. This comes following feedback from the European Medicines Agency (EMA) related to ProQR’s sepofarsen for Leber Congenital Amaurosis type 10 (LCA10).
… focuses on developing potential medicines using our Axiomer ® RNA editing platform technology. Strategic … drive the advancement of an early-stage technology, like Axiomer , closer to the clinic. In any global licensing and … of high unmet need Lenka van Sint Fiet, Director AxiomerAxiomer technology ProQR’s Axiomer ® platform …
ProQR has announced the completion of an in-depth strategic review designed to deliver on our commitment to advance RNA therapies for diseases with high unmet need. We are also sharing additional analyses of the sepofarsen Illuminate trial.
